Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Ipsen

Finance Watch: Regulus Shrinks To Preserve Cash, Ironwood Cuts Jobs Ahead Of Split

Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.

Financing Business Strategies

Pipeline Watch: Phase III Progress With Tecentriq, Rolontis And ADV7103

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Merz Neurology Business Boosted By Xeomin Sialorrhea OK

The drug has become the only neurotoxin to be approved for excessive drooling in the US, giving Merz an advantage over rivals such as Allergan's Botox to treat a condition that affects over 600,000 adults across the Atlantic.

Neurology Approvals

Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial

Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Beaufour Ipsen
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • David Meek, CEO
    Aymeric Le Chatelier, EVP, Fin. & CFO
    Alexandre Lebeaut, MD, EVP, R&D & CSO
    Ivana Magovcevic-Liebisch, EVP, CBO
  • Contact Info
  • Ipsen
    Phone: (33) 1 58 33 50 00
    65 quai George Gorse
    Boulogne-Billancourt, 92100
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register